Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron’s Promising Phase 3 Results

This article was written by Follow With a background as an RN and an MBA, I…

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO)

This article was written by Follow Terry Chrisomalis is a private investor in the Biotech sector…